nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—Photosensitivity—Lisinopril—systemic scleroderma	0.00564	0.00564	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Mycophenolate mofetil—systemic scleroderma	0.00561	0.00561	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Captopril—systemic scleroderma	0.00551	0.00551	CcSEcCtD
Methyclothiazide—Haemolytic anaemia—Lisinopril—systemic scleroderma	0.00548	0.00548	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Captopril—systemic scleroderma	0.00534	0.00534	CcSEcCtD
Methyclothiazide—Muscle spasms—Pentoxifylline—systemic scleroderma	0.00534	0.00534	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Mycophenolate mofetil—systemic scleroderma	0.00532	0.00532	CcSEcCtD
Methyclothiazide—Jaundice—Captopril—systemic scleroderma	0.00525	0.00525	CcSEcCtD
Methyclothiazide—Vision blurred—Pentoxifylline—systemic scleroderma	0.00523	0.00523	CcSEcCtD
Methyclothiazide—Cramp muscle—Leflunomide—systemic scleroderma	0.00519	0.00519	CcSEcCtD
Methyclothiazide—Pancreatitis—Azathioprine—systemic scleroderma	0.00517	0.00517	CcSEcCtD
Methyclothiazide—Agitation—Pentoxifylline—systemic scleroderma	0.0051	0.0051	CcSEcCtD
Methyclothiazide—Agranulocytosis—Captopril—systemic scleroderma	0.00503	0.00503	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Mycophenolic acid—systemic scleroderma	0.00502	0.00502	CcSEcCtD
Methyclothiazide—Glycosuria—Prednisone—systemic scleroderma	0.005	0.005	CcSEcCtD
Methyclothiazide—Leukopenia—Pentoxifylline—systemic scleroderma	0.00497	0.00497	CcSEcCtD
Methyclothiazide—Cramp muscle—Mycophenolic acid—systemic scleroderma	0.00495	0.00495	CcSEcCtD
Methyclothiazide—Pancreatitis—Leflunomide—systemic scleroderma	0.00488	0.00488	CcSEcCtD
Methyclothiazide—Haemolytic anaemia—Mycophenolate mofetil—systemic scleroderma	0.0048	0.0048	CcSEcCtD
Methyclothiazide—Pneumonia—Azathioprine—systemic scleroderma	0.00473	0.00473	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Azathioprine—systemic scleroderma	0.00466	0.00466	CcSEcCtD
Methyclothiazide—Pancreatitis—Mycophenolic acid—systemic scleroderma	0.00466	0.00466	CcSEcCtD
Methyclothiazide—Erythema multiforme—Captopril—systemic scleroderma	0.00457	0.00457	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00453	0.00453	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Lisinopril—systemic scleroderma	0.00452	0.00452	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Leflunomide—systemic scleroderma	0.00449	0.00449	CcSEcCtD
Methyclothiazide—Pneumonia—Leflunomide—systemic scleroderma	0.00446	0.00446	CcSEcCtD
Methyclothiazide—Cramp muscle—Lisinopril—systemic scleroderma	0.00446	0.00446	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.00444	0.00444	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Leflunomide—systemic scleroderma	0.0044	0.0044	CcSEcCtD
Methyclothiazide—Agranulocytosis—Azathioprine—systemic scleroderma	0.00439	0.00439	CcSEcCtD
Methyclothiazide—Jaundice—Leflunomide—systemic scleroderma	0.00433	0.00433	CcSEcCtD
Methyclothiazide—Anorexia—Pentoxifylline—systemic scleroderma	0.00432	0.00432	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.00428	0.00428	CcSEcCtD
Methyclothiazide—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Methyclothiazide—Pancreatitis—Lisinopril—systemic scleroderma	0.00419	0.00419	CcSEcCtD
Methyclothiazide—Vasculitis—Prednisone—systemic scleroderma	0.00415	0.00415	CcSEcCtD
Methyclothiazide—Agranulocytosis—Leflunomide—systemic scleroderma	0.00414	0.00414	CcSEcCtD
Methyclothiazide—Jaundice—Mycophenolic acid—systemic scleroderma	0.00413	0.00413	CcSEcCtD
Methyclothiazide—Erythema multiforme—Azathioprine—systemic scleroderma	0.00399	0.00399	CcSEcCtD
Methyclothiazide—Vision blurred—Captopril—systemic scleroderma	0.00397	0.00397	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Mycophenolate mofetil—systemic scleroderma	0.00396	0.00396	CcSEcCtD
Methyclothiazide—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Methyclothiazide—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00394	0.00394	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Mometasone—systemic scleroderma	0.00391	0.00391	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.0039	0.0039	CcSEcCtD
Methyclothiazide—Constipation—Pentoxifylline—systemic scleroderma	0.00388	0.00388	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Lisinopril—systemic scleroderma	0.00386	0.00386	CcSEcCtD
Methyclothiazide—Pneumonia—Lisinopril—systemic scleroderma	0.00384	0.00384	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Methyclothiazide—Erythema multiforme—Leflunomide—systemic scleroderma	0.00377	0.00377	CcSEcCtD
Methyclothiazide—Anorexia—Mometasone—systemic scleroderma	0.00373	0.00373	CcSEcCtD
Methyclothiazide—Jaundice—Lisinopril—systemic scleroderma	0.00372	0.00372	CcSEcCtD
Methyclothiazide—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.00367	0.00367	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Methotrexate—systemic scleroderma	0.00365	0.00365	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Prednisone—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Methyclothiazide—Urticaria—Pentoxifylline—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Methyclothiazide—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00358	0.00358	CcSEcCtD
Methyclothiazide—Agranulocytosis—Lisinopril—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Methyclothiazide—Paraesthesia—Mometasone—systemic scleroderma	0.00351	0.00351	CcSEcCtD
Methyclothiazide—Malnutrition—Leflunomide—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Methyclothiazide—Vasculitis—Methotrexate—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Methotrexate—systemic scleroderma	0.00345	0.00345	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Captopril—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Methyclothiazide—Decreased appetite—Mometasone—systemic scleroderma	0.0034	0.0034	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00338	0.00338	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Captopril—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Methyclothiazide—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Methyclothiazide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00334	0.00334	CcSEcCtD
Methyclothiazide—Muscle spasms—Leflunomide—systemic scleroderma	0.00333	0.00333	CcSEcCtD
Methyclothiazide—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Methyclothiazide—Leukopenia—Azathioprine—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Methyclothiazide—Vascular purpura—Prednisone—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Methyclothiazide—Anorexia—Captopril—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Methyclothiazide—Vision blurred—Leflunomide—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Methyclothiazide—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.00326	0.00326	CcSEcCtD
Methyclothiazide—Asthenia—Pentoxifylline—systemic scleroderma	0.00325	0.00325	CcSEcCtD
Methyclothiazide—Erythema multiforme—Lisinopril—systemic scleroderma	0.00324	0.00324	CcSEcCtD
Methyclothiazide—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Methotrexate—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Methyclothiazide—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Methyclothiazide—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Methyclothiazide—Vertigo—Leflunomide—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Methyclothiazide—Leukopenia—Leflunomide—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Methyclothiazide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Methyclothiazide—Body temperature increased—Mometasone—systemic scleroderma	0.00309	0.00309	CcSEcCtD
Methyclothiazide—Paraesthesia—Captopril—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Methyclothiazide—Purpura—Prednisone—systemic scleroderma	0.00305	0.00305	CcSEcCtD
Methyclothiazide—Agitation—Mycophenolic acid—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Methotrexate—systemic scleroderma	0.00301	0.00301	CcSEcCtD
Methyclothiazide—Dizziness—Pentoxifylline—systemic scleroderma	0.003	0.003	CcSEcCtD
Methyclothiazide—Decreased appetite—Captopril—systemic scleroderma	0.00299	0.00299	CcSEcCtD
Methyclothiazide—Malnutrition—Lisinopril—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Methyclothiazide—Vertigo—Mycophenolic acid—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Methyclothiazide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Methyclothiazide—Constipation—Captopril—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00293	0.00293	CcSEcCtD
Methyclothiazide—Vomiting—Pentoxifylline—systemic scleroderma	0.00288	0.00288	CcSEcCtD
Methyclothiazide—Muscle spasms—Lisinopril—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Methyclothiazide—Rash—Pentoxifylline—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Methyclothiazide—Dermatitis—Pentoxifylline—systemic scleroderma	0.00285	0.00285	CcSEcCtD
Methyclothiazide—Headache—Pentoxifylline—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Methyclothiazide—Vision blurred—Lisinopril—systemic scleroderma	0.00281	0.00281	CcSEcCtD
Methyclothiazide—Asthenia—Mometasone—systemic scleroderma	0.00281	0.00281	CcSEcCtD
Methyclothiazide—Photosensitivity—Methotrexate—systemic scleroderma	0.0028	0.0028	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00277	0.00277	CcSEcCtD
Methyclothiazide—Body temperature increased—Captopril—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Methyclothiazide—Anorexia—Leflunomide—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Methyclothiazide—Nausea—Pentoxifylline—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Methyclothiazide—Vertigo—Lisinopril—systemic scleroderma	0.00268	0.00268	CcSEcCtD
Methyclothiazide—Diarrhoea—Mometasone—systemic scleroderma	0.00268	0.00268	CcSEcCtD
Methyclothiazide—Leukopenia—Lisinopril—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00264	0.00264	CcSEcCtD
Methyclothiazide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Methyclothiazide—Anorexia—Mycophenolic acid—systemic scleroderma	0.00257	0.00257	CcSEcCtD
Methyclothiazide—Paraesthesia—Leflunomide—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Methyclothiazide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Methyclothiazide—Pancreatitis—Prednisone—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Methyclothiazide—Vomiting—Mometasone—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Methyclothiazide—Rash—Mometasone—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Methyclothiazide—Asthenia—Captopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Methyclothiazide—Dermatitis—Mometasone—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Methyclothiazide—Decreased appetite—Leflunomide—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Methyclothiazide—Headache—Mometasone—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Methyclothiazide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Methyclothiazide—Constipation—Leflunomide—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Methyclothiazide—Agitation—Mycophenolate mofetil—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Methyclothiazide—Body temperature increased—Azathioprine—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Methyclothiazide—Diarrhoea—Captopril—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Methyclothiazide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Methyclothiazide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Methyclothiazide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Methyclothiazide—Nausea—Mometasone—systemic scleroderma	0.00232	0.00232	CcSEcCtD
Methyclothiazide—Anorexia—Lisinopril—systemic scleroderma	0.00232	0.00232	CcSEcCtD
Methyclothiazide—Constipation—Mycophenolic acid—systemic scleroderma	0.00231	0.00231	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Prednisone—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Methyclothiazide—Dizziness—Captopril—systemic scleroderma	0.00227	0.00227	CcSEcCtD
Methyclothiazide—Urticaria—Leflunomide—systemic scleroderma	0.00225	0.00225	CcSEcCtD
Methyclothiazide—Body temperature increased—Leflunomide—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Methyclothiazide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Methyclothiazide—Paraesthesia—Lisinopril—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Methyclothiazide—Vomiting—Captopril—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Methyclothiazide—Rash—Captopril—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Methyclothiazide—Dermatitis—Captopril—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Methyclothiazide—Headache—Captopril—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Methyclothiazide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Methyclothiazide—Decreased appetite—Lisinopril—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Methyclothiazide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Methyclothiazide—Pancreatitis—Methotrexate—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Methyclothiazide—Constipation—Lisinopril—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Methyclothiazide—Diarrhoea—Azathioprine—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Methyclothiazide—Nausea—Captopril—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Methyclothiazide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Methyclothiazide—Asthenia—Leflunomide—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Methyclothiazide—Dizziness—Azathioprine—systemic scleroderma	0.00198	0.00198	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Methyclothiazide—Asthenia—Mycophenolic acid—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Methyclothiazide—Diarrhoea—Leflunomide—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Methyclothiazide—Urticaria—Lisinopril—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Methyclothiazide—Body temperature increased—Lisinopril—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Methyclothiazide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Methyclothiazide—Vomiting—Azathioprine—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Methyclothiazide—Pneumonia—Methotrexate—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Methyclothiazide—Rash—Azathioprine—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Methyclothiazide—Dermatitis—Azathioprine—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Methyclothiazide—Headache—Azathioprine—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Methyclothiazide—Dizziness—Leflunomide—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Methyclothiazide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Methyclothiazide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Methyclothiazide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Methyclothiazide—Vomiting—Leflunomide—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Methyclothiazide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Methyclothiazide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Methyclothiazide—Rash—Leflunomide—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Methyclothiazide—Dermatitis—Leflunomide—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Methyclothiazide—Nausea—Azathioprine—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Methyclothiazide—Headache—Leflunomide—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Methyclothiazide—Malnutrition—Prednisone—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Methyclothiazide—Agranulocytosis—Methotrexate—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Methyclothiazide—Asthenia—Lisinopril—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Methyclothiazide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Methyclothiazide—Rash—Mycophenolic acid—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Methyclothiazide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Methyclothiazide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Methyclothiazide—Headache—Mycophenolic acid—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Methyclothiazide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Methyclothiazide—Nausea—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Methyclothiazide—Vision blurred—Prednisone—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Methyclothiazide—Diarrhoea—Lisinopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Methyclothiazide—Agitation—Prednisone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Methyclothiazide—Dizziness—Lisinopril—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Methyclothiazide—Erythema multiforme—Methotrexate—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Methyclothiazide—Nausea—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Methyclothiazide—Vertigo—Prednisone—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Methyclothiazide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Methyclothiazide—Vomiting—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Methyclothiazide—Rash—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Methyclothiazide—Dermatitis—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Methyclothiazide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Methyclothiazide—Headache—Lisinopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Methyclothiazide—Malnutrition—Methotrexate—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Methyclothiazide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Methyclothiazide—Nausea—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Methyclothiazide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Methyclothiazide—Vision blurred—Methotrexate—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Methyclothiazide—Anorexia—Prednisone—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Methyclothiazide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Methyclothiazide—Rash—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Methyclothiazide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Methyclothiazide—Headache—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Methyclothiazide—Vertigo—Methotrexate—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Methyclothiazide—Leukopenia—Methotrexate—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Methyclothiazide—Paraesthesia—Prednisone—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Methyclothiazide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Methyclothiazide—Decreased appetite—Prednisone—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Methyclothiazide—Constipation—Prednisone—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Methyclothiazide—Anorexia—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Methyclothiazide—Urticaria—Prednisone—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Methyclothiazide—Body temperature increased—Prednisone—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Methyclothiazide—Paraesthesia—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Methyclothiazide—Hypersensitivity—Prednisone—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Methyclothiazide—Decreased appetite—Methotrexate—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Methyclothiazide—Asthenia—Prednisone—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Methyclothiazide—Diarrhoea—Prednisone—systemic scleroderma	0.000988	0.000988	CcSEcCtD
Methyclothiazide—Urticaria—Methotrexate—systemic scleroderma	0.000959	0.000959	CcSEcCtD
Methyclothiazide—Dizziness—Prednisone—systemic scleroderma	0.000955	0.000955	CcSEcCtD
Methyclothiazide—Body temperature increased—Methotrexate—systemic scleroderma	0.000954	0.000954	CcSEcCtD
Methyclothiazide—Vomiting—Prednisone—systemic scleroderma	0.000919	0.000919	CcSEcCtD
Methyclothiazide—Rash—Prednisone—systemic scleroderma	0.000911	0.000911	CcSEcCtD
Methyclothiazide—Dermatitis—Prednisone—systemic scleroderma	0.00091	0.00091	CcSEcCtD
Methyclothiazide—Headache—Prednisone—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Methyclothiazide—Hypersensitivity—Methotrexate—systemic scleroderma	0.00089	0.00089	CcSEcCtD
Methyclothiazide—Asthenia—Methotrexate—systemic scleroderma	0.000866	0.000866	CcSEcCtD
Methyclothiazide—Nausea—Prednisone—systemic scleroderma	0.000858	0.000858	CcSEcCtD
Methyclothiazide—Diarrhoea—Methotrexate—systemic scleroderma	0.000826	0.000826	CcSEcCtD
Methyclothiazide—Dizziness—Methotrexate—systemic scleroderma	0.000798	0.000798	CcSEcCtD
Methyclothiazide—Vomiting—Methotrexate—systemic scleroderma	0.000768	0.000768	CcSEcCtD
Methyclothiazide—Rash—Methotrexate—systemic scleroderma	0.000761	0.000761	CcSEcCtD
Methyclothiazide—Dermatitis—Methotrexate—systemic scleroderma	0.000761	0.000761	CcSEcCtD
Methyclothiazide—Headache—Methotrexate—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Methyclothiazide—Nausea—Methotrexate—systemic scleroderma	0.000717	0.000717	CcSEcCtD
